Regeneron, Avalanche Collaborate on $640M Gene Therapy Deal

May 07, 2014

Genetic Engineering & Biotechnology News

Regeneron Pharmaceuticals will use Avalanche Biotechnologies’ adeno-associated virus (AAV)-based drug-delivery platform in a collaboration to commercialize its lead drug and new gene therapy products for ophthalmologic diseases, the companies said. The deal could net Avalanche more than $640 million. Under the collaboration, Regeneron will apply the Avalanche Ocular BioFactory to discover and develop gene therapy vectors for ophthalmology. BioFactory is designed to use the body's own cells to produce therapeutic protein after only a single injection. That in turn blocks VEGF signaling, treating the disease. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments